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　We experienced 20 patients with distal bile duct carcinoma from May, 1997 to December, 2007. The male/female 
ratio was 11/9 and the average age was 69.6 years. The operative procedures were as follows：pancreaticoduo-
denectomy (PD), 9；pyrolus preserving pancreaticoduodenectomy (PPPD), 8；subtotal stomach preserving pancrea-
ticoduodenectomy (SSPPD), 2 and hepatico-jejunostomy without resection, 1. We performed a clinicopathological 
study on 16 patients with distal bile duct carcinoma, excluding 3 operation-related deaths and 1 unresectable case. The 
cumulative survival rate was 70% at 3 years and 11% at 5 years. The 3-year survival rates at fStageⅡ, fStageⅣa and 
fStageⅣb were 100%, 80% and 0%, respectively. Log-rank analysis revealed that pathological pancreatic and 
duodenal invasion and curative resectability may be prognostic factors, while lymph node metastasis and perineural 
and stump invasion did not affect prognosis. Six recurrences in the 11 curative resection cases (54.5%) were 
observed；therefore, postoperative systemic chemotherapy is warranted to curtail recurrence in advanced distal bile 
duct carcinoma.
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